scholarly journals Can We Use the Silodosin as Second Line Treatment of Benign Prostate Hyperplasia?

2020 ◽  
Author(s):  
Bekir Voyvoda ◽  
Ömür Memik ◽  
Murat Üstüner ◽  
Onur Karslı ◽  
Levent Özcan
Keyword(s):  
Surgical Treatment ◽  
Benign Prostate Hyperplasia ◽  
Symptom Control ◽  
Routine Clinical Practice ◽  
Prostate Hyperplasia ◽  
Blocker Therapy ◽  
The Third ◽  
Group 2 ◽  
Benign Prostate ◽  
Group 1

Objective: Our study aimed to the efficacy of silodosin in patients with LUTS associated with BPH who were not-responder to previous ARs blocker therapy. Methods: Patients who did not benefit from alpha blockers treatment, but did not want surgical treatment are included in this study. At enrollment, 75 patients and 75 patients were assigned to group 1 and group 2, respectively. Group 1 received silodosin 8 mg, group 2 received their previous α blocker. Results: Although, in group 1 mean IPSS score at baseline was 20,81±0,97, and it significantly decreased to 17,12±1,25 at third months, in group 2 no significant changes were observed. On the other hand in group 1 a decrease was also observed for both IPSS sub score was significantly reduced at third months, when it is compared with baseline. At the end of the third month, a significant improvement in this parameter was observed after switching to silodosin, as compared with first value (p< 0,05). As to the residual urine, significant improvement was observed in the silodosin group but no significant improvement was observed in group 2. Conclusion: This study was conducted to investigate the effectiveness and safety of silodosin in patients with BPH who had not achieved satisfactory symptom control with other α blockers in routine clinical practice before surgical treatment. Thus, at least patients who have different comorbidities will be protected from morbidities of surgery.

scholarly journals Can We Use the Silodosin as Second Line Treatment of Benign Prostate Hyperplasia?

2021 ◽  
Author(s):  
Bekir Voyvoda ◽  
Onur Memik ◽  
Onur Karslı ◽  
Murat Üstüner ◽  
Levent Özcan
Keyword(s):  
Surgical Treatment ◽  
Symptom Relief ◽  
Routine Practice ◽  
Prostate Hyperplasia ◽  
Blocker Therapy ◽  
Alpha Blocker ◽  
The Third ◽  
Voiding Symptoms ◽  
Group 2 ◽  
Group 1

Objective: We aimed to investigate the efficacy of silodosin in patients with lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH) refractory to previous α-adrenergic receptor (AR) blocker therapy. Materials and Methods: Patients who did not benefit from alpha-blocker therapy but avoided surgical treatment constitute the population of our study. Seventy-five patients were studied in each group; Group 1 was given 8 mg of silodosin, while Group 2 continued the previous alpha-blocker treatment. Results: The initial mean international prostate symptom score (IPSS) was calculated as 20.81±0.97 in Group 1, in the third month there was a decrease of 17.12±1.25 (p<0.05). No significant change was observed in Group 2. In addition, a significant decrease was observed in IPSS subscores (storage and voiding symptoms) in Group 1 compared to baseline at the third month. There was an improvement in residual urine in the silodosin group and no improvement in the other group. Conclusion: In patients with BPH who refuse surgical treatment and could not achieve adequate symptom relief with other α-blockers in routine practice, silodosin was found superior in terms of LUTS recovery. Silodosin is also an effective option in patients who cannot undergo surgical treatment due to comorbidities.

New surgical treatment options in patients with benign prostate hyperplasia (BPH)

2003 ◽  
Author(s):  
Werner T. W. de Riese ◽  
Thomas Nelius ◽  
David R. Aronoff ◽  
Bernhard T. Mittemeyer
Keyword(s):  
Surgical Treatment ◽  
Benign Prostate Hyperplasia ◽  
Treatment Options ◽  
Prostate Hyperplasia ◽  
Benign Prostate

scholarly journals Salvage Holmium laser enucleation of prostate to treat recurring benign prostatic hyperplasia

2014 ◽  
Vol 8 (3-4) ◽  
pp. 235 ◽  
Author(s):  
Jin Kyu Oh ◽  
Jungbum Bae ◽  
Chang Wook Jeong ◽  
Jae-Seung Paick ◽  
Seung-June Oh
Keyword(s):  
Operation Time ◽  
Holmium Laser ◽  
Time Duration ◽  
Prostate Hyperplasia ◽  
Laser Enucleation ◽  
Group 2 ◽  
Benign Prostate ◽  
Holmium Laser Enucleation ◽  
Anatomical Plane ◽  
Group 1

Introduction: The Holmium laser enucleation of the prostate (HoLEP) technique to remove residual adenoma has not been reported. Salvage HoLEP enables anatomical enucleation of residual adenoma in patients who have previously undergone surgical treatment. We describe not only anatomical insights into the frequent location of adenoma recurrence, but also the feasibility of the salvage HoLEP technique.Methods: We retrospectively reviewed a database containing HoLEP video records for 35 patients out of a total of 535 individuals on whom HoLEP was performed by 2 surgeons (SJO & JSP) between July 2008 and June 2011. Group 1 consisted of patients who underwent salvage HoLEP due to recurring adenoma and Group 2 of patients who underwent HoLEP as an initially surgical management to treat benign prostate hyperplasia (BPH). We compared the dataset of pre-, intra- and postoperative parameters between Groups 1 and 2.Results: In the analysis of the video records of Group 1 (n = 35), there was significant remnant tissue around the verumontanum and the lateral lobes were also incompletely removed by previous conventional procedures. When we compared pre-, intra- and postoperative parameters between the 2 groups, there were no significant differences, including operation time, duration of hospital stay. However, the duration of the catheterization of Group 1 was shorter than that of Group 2 (1.38 ± 0.55 vs. 1.90 ± 1.81 days, p < 0.001).Conclusions: Even for cases of residual BPH, salvage HoLEP is a feasible and effective procedure for treating residual adenoma along the anatomical plane.

C177 Postoperative complications after surgical treatment of benign prostate hyperplasia

2013 ◽  
Vol 12 (4) ◽  
pp. e1285, C177a-e1285, C177b
Author(s):  
M.K. Alchinbayev ◽  
M.A. Malikh ◽  
M.T. Batyrbekov ◽  
K.M. Abdilmanov ◽  
I.B. Mansurova
Keyword(s):  
Surgical Treatment ◽  
Postoperative Complications ◽  
Benign Prostate Hyperplasia ◽  
Prostate Hyperplasia ◽  
Benign Prostate

scholarly journals STRUCTURE OF PROVISION OF URGENT AND PLANNED SURGICAL CARE TO PATIENTS WITH BENIGN PROSTATE HYPERPLASIA IN RYAZAN RE-GION

2020 ◽  
Vol 8 (4) ◽  
pp. 495-501
Author(s):  
I.S. Sobennikov ◽  
◽  
V.B. Filimonov ◽  
R.V. Vasin ◽  
◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Benign Prostate Hyperplasia ◽  
Clinical Symptoms ◽  
Statistical Processing ◽  
Surgical Care ◽  
Urgent Care ◽  
Transurethral Resection Of Prostate ◽  
Prostate Hyperplasia ◽  
Surgical Interventions ◽  
Benign Prostate

Aim. To study the status of provision of planned and urgent care to patients with benign prostate hyperplasia (BPH) in round-the-clock urological hospitals of the Ryazan region in recent 5 years. Materials and Methods. Statistical processing of the data for 2015-2020 obtained from medical statistics services of urological hospitals of Ryazan was performed. The following parameters were studied: the average age of patients who turned to emergency room with the diagnosis of acute retention of urine; the amount of surgical interventions (cystectomies) per months and years of the reporting period: open adenomectomy (in the following modifications: transvesical ade-nomectomy, retropubic adenomectomy), transurethral resection of prostate. Results. A high amount of referral of patients with BPH with clinical symptoms of acute reten-tion of urine was identified. The quantity and the share of palliative surgeries in the structure of patients with BPH stays at a high level. A tendency to growth in the amount of minimally inva-sive operations in surgical treatment for BPH is noted. Conclusion. The analysis of statistical data indicates the need for improvement of the quality of dispensary observation of patients with BPH, and improvement of methods of minimally inva-sive surgical treatment of BPH.

scholarly journals The Predictive Factor for Favorable Outcome after Surgical Treatment of Benign Prostate Hyperplasia Performed by Young Urologist - Is Surgical Modality Important in Beginner Urologists?

2020 ◽  
Author(s):  
Ki Hong Kim ◽  
Si Hyun Kim ◽  
Hee Jo Yang ◽  
Doo Sang Kim ◽  
Chang Ho Lee ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Predictive Factors ◽  
Benign Prostate Hyperplasia ◽  
Favorable Outcome ◽  
Transurethral Resection Of Prostate ◽  
Prostate Hyperplasia ◽  
Institutional Review ◽  
Surgical Modality ◽  
Response Group ◽  
Benign Prostate

Abstract Background: To identify predictive factors for favorable outcomes after surgical treatments that were performed by beginner urologists in patients with benign prostate hyperplasia (BPH), we retrospectively evaluated outcomes after holmium laser enucleation of the prostate (HoLEP) and transurethral resection of prostate (TURP) that were performed by two young urologists.Methods: Of 80 patients who were treated with HoLEP or TURP, 31 (HoLEP) and 36 (TURP) patients who were followed up for 3 months were enrolled in this study. Preoperative and perioperative variables were evaluated to identify predictive factors for favorable outcome after surgical treatment for BPH.Results: At 3 months postoperative after HoLEP or TURP, the median decrease in IPSS was 13.0. Patients whose IPSS decreased by over 13 points were categorized into a favorable response group after HoLEP or TURP. Univariate and multivariate logistic regression analyses were performed to identify predictors of favorable outcomes at 3 months after HoLEP or TURP, and the preoperative IPSS was identified as an independent predictor for favorable outcomes. Conclusions: When young urologists plan to perform surgical treatment for BPH, they should consider that the severity of symptoms is the most important factor for favorable outcomes. The type of surgical modality for managing BPH is less important. Trial registration : Soonchunhyang university institutional review board approval (No. 2017-07-022)

Sign in / Sign up

Export Citation Format

Share Document